KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) Non Operating Income (2016 - 2026)

Eli Lilly filings provide 18 years of Non Operating Income readings, the most recent being -$65.0 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 72.8% to -$65.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$397.0 million, a 18.16% increase, with the full-year FY2025 number at -$571.0 million, down 160.73% from a year prior.
  • Non Operating Income hit -$65.0 million in Q1 2026 for Eli Lilly, up from -$108.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $260.0 million in Q4 2022 to a low of -$350.7 million in Q1 2022.
  • Median Non Operating Income over the past 5 years was -$90.6 million (2025), compared with a mean of -$63.5 million.
  • Biggest five-year swings in Non Operating Income: surged 436.35% in 2022 and later crashed 981.92% in 2025.
  • Eli Lilly's Non Operating Income stood at $260.0 million in 2022, then plummeted by 53.35% to $121.3 million in 2023, then tumbled by 191.1% to -$110.5 million in 2024, then increased by 1.99% to -$108.3 million in 2025, then surged by 39.98% to -$65.0 million in 2026.
  • The last three reported values for Non Operating Income were -$65.0 million (Q1 2026), -$108.3 million (Q4 2025), and -$133.1 million (Q3 2025) per Business Quant data.